The clinical significance of antiphospholipid antibodies

Research output: Contribution to journalArticle

Abstract

The antiphospholipid syndrome is defined as the association between the presence of antiphospholipid antibodies, detected as anticardiolipin antibodies and/or lupus anticoagulant, and a history of either arterial or venous thrombosis and/or recurrent pregnancy loss. Because thrombosis may occur in virtually any organ system, diagnosing the antiphospholipid syndrome and taking appropriate anticoagulation measures are important considerations in all medical specialties. Antiphospholipid antibody-associated thrombosis tends to recur. Antithrombotic prophylaxis to prevent recurrences is therefore needed. Prophylaxis in individuals with circulating antiphospholipid antibodies who have no history of thrombosis is still controversial. Although direct evidence for a pathogenetic role of antiphospholipid antibodies in the development of thrombosis is still lacking, recent studies suggest that it is causative rather than coincidental. New insights on the possible mechanisms leading to thrombosis were provided by the discovery of the serum cofactor (β2-GPI), a coagulation inhibitor which is required for binding of anticardiolipin antibodies to cardiolipin. More recently, patients with antiphospholipid antibodies were found to possess autoantibodies directed against other coagulation factors, including prothrombin, protein C and protein S. Future studies should clarify whether these different antigenic specificities are associated with particular clinical events and assess the risk of thrombosis associated with the presence of antiphospholipid antibodies in asymptomatic individuals.

Original languageEnglish
Pages (from-to)159-163
Number of pages5
JournalAnnals of Medicine
Volume29
Issue number2
Publication statusPublished - 1997

Fingerprint

Antiphospholipid Antibodies
Thrombosis
Anticardiolipin Antibodies
Antiphospholipid Syndrome
Lupus Coagulation Inhibitor
Cardiolipins
Blood Coagulation Factors
Protein S
Prothrombin
Protein C
Venous Thrombosis
Autoantibodies
Epitopes
Medicine
Recurrence
Pregnancy
Serum

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Vascular thrombosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The clinical significance of antiphospholipid antibodies. / Martini, Alberto; Ravelli, Angelo.

In: Annals of Medicine, Vol. 29, No. 2, 1997, p. 159-163.

Research output: Contribution to journalArticle

@article{a53b4092462a4d238e3d56ecaa5b3d5c,
title = "The clinical significance of antiphospholipid antibodies",
abstract = "The antiphospholipid syndrome is defined as the association between the presence of antiphospholipid antibodies, detected as anticardiolipin antibodies and/or lupus anticoagulant, and a history of either arterial or venous thrombosis and/or recurrent pregnancy loss. Because thrombosis may occur in virtually any organ system, diagnosing the antiphospholipid syndrome and taking appropriate anticoagulation measures are important considerations in all medical specialties. Antiphospholipid antibody-associated thrombosis tends to recur. Antithrombotic prophylaxis to prevent recurrences is therefore needed. Prophylaxis in individuals with circulating antiphospholipid antibodies who have no history of thrombosis is still controversial. Although direct evidence for a pathogenetic role of antiphospholipid antibodies in the development of thrombosis is still lacking, recent studies suggest that it is causative rather than coincidental. New insights on the possible mechanisms leading to thrombosis were provided by the discovery of the serum cofactor (β2-GPI), a coagulation inhibitor which is required for binding of anticardiolipin antibodies to cardiolipin. More recently, patients with antiphospholipid antibodies were found to possess autoantibodies directed against other coagulation factors, including prothrombin, protein C and protein S. Future studies should clarify whether these different antigenic specificities are associated with particular clinical events and assess the risk of thrombosis associated with the presence of antiphospholipid antibodies in asymptomatic individuals.",
keywords = "Antiphospholipid antibodies, Antiphospholipid syndrome, Vascular thrombosis",
author = "Alberto Martini and Angelo Ravelli",
year = "1997",
language = "English",
volume = "29",
pages = "159--163",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The clinical significance of antiphospholipid antibodies

AU - Martini, Alberto

AU - Ravelli, Angelo

PY - 1997

Y1 - 1997

N2 - The antiphospholipid syndrome is defined as the association between the presence of antiphospholipid antibodies, detected as anticardiolipin antibodies and/or lupus anticoagulant, and a history of either arterial or venous thrombosis and/or recurrent pregnancy loss. Because thrombosis may occur in virtually any organ system, diagnosing the antiphospholipid syndrome and taking appropriate anticoagulation measures are important considerations in all medical specialties. Antiphospholipid antibody-associated thrombosis tends to recur. Antithrombotic prophylaxis to prevent recurrences is therefore needed. Prophylaxis in individuals with circulating antiphospholipid antibodies who have no history of thrombosis is still controversial. Although direct evidence for a pathogenetic role of antiphospholipid antibodies in the development of thrombosis is still lacking, recent studies suggest that it is causative rather than coincidental. New insights on the possible mechanisms leading to thrombosis were provided by the discovery of the serum cofactor (β2-GPI), a coagulation inhibitor which is required for binding of anticardiolipin antibodies to cardiolipin. More recently, patients with antiphospholipid antibodies were found to possess autoantibodies directed against other coagulation factors, including prothrombin, protein C and protein S. Future studies should clarify whether these different antigenic specificities are associated with particular clinical events and assess the risk of thrombosis associated with the presence of antiphospholipid antibodies in asymptomatic individuals.

AB - The antiphospholipid syndrome is defined as the association between the presence of antiphospholipid antibodies, detected as anticardiolipin antibodies and/or lupus anticoagulant, and a history of either arterial or venous thrombosis and/or recurrent pregnancy loss. Because thrombosis may occur in virtually any organ system, diagnosing the antiphospholipid syndrome and taking appropriate anticoagulation measures are important considerations in all medical specialties. Antiphospholipid antibody-associated thrombosis tends to recur. Antithrombotic prophylaxis to prevent recurrences is therefore needed. Prophylaxis in individuals with circulating antiphospholipid antibodies who have no history of thrombosis is still controversial. Although direct evidence for a pathogenetic role of antiphospholipid antibodies in the development of thrombosis is still lacking, recent studies suggest that it is causative rather than coincidental. New insights on the possible mechanisms leading to thrombosis were provided by the discovery of the serum cofactor (β2-GPI), a coagulation inhibitor which is required for binding of anticardiolipin antibodies to cardiolipin. More recently, patients with antiphospholipid antibodies were found to possess autoantibodies directed against other coagulation factors, including prothrombin, protein C and protein S. Future studies should clarify whether these different antigenic specificities are associated with particular clinical events and assess the risk of thrombosis associated with the presence of antiphospholipid antibodies in asymptomatic individuals.

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Vascular thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0031001114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031001114&partnerID=8YFLogxK

M3 - Article

C2 - 9187233

AN - SCOPUS:0031001114

VL - 29

SP - 159

EP - 163

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 2

ER -